granisetron has been researched along with epirubicin in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (50.00) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 3 (16.67) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Behnam Motlagh, P; Grankvist, K; Henriksson, R | 1 |
| Ang, PT; Khoo, KS; Tan, EH | 1 |
| Kitada, M; Sawaragi, I | 1 |
| Jantunen, IT; Kataja, VV; Muhonen, TT; Parviainen, T | 1 |
| Ionta, MT; Massidda, B | 1 |
| Fujimori, R; Sanada, H; Sekine, M; Serikawa, T; Shichiri, K; Tanaka, K | 1 |
| Andersen, LJ; Dombernowsky, P; Havsteen, H; Herrstedt, J; Kjaer, M; Kjaerbøl, AG; Langer, SW; Lund, H; Sigsgaard, T | 1 |
| Bauduer, F; Coiffier, B; Desablens, B | 1 |
| Abali, H; Guler, N; Oyan, B | 1 |
| Kim, SJ; Miyoshi, Y; Noguchi, S; Taguchi, T; Tamaki, Y; Tanji, Y | 1 |
| Ito, Y; Tomono, H; Watanabe, T | 1 |
| Eksborg, S; Lönnqvist, PA; Öbrink, E; Oddby-Muhrbeck, E; Rotstein, S | 1 |
| Araz, M; Artac, M; Beypinar, I; Inci, F; Karaagac, M; Koral, L; Korkmaz, L; Uysal, M | 1 |
| Aogi, K; Baba, M; Chiba, Y; Fujiwara, K; Hirano, G; Imamura, CK; Imoto, S; Matsumoto, K; Matsuura, K; Miyazaki, C; Naito, Y; Osaki, A; Saeki, T; Sato, K; Takahashi, M; Takano, T; Tamura, K; Tokunaga, S; Yanagihara, K | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for granisetron and epirubicin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
11 trial(s) available for granisetron and epirubicin
| Article | Year |
|---|---|
Control of emesis by intravenous granisetron in breast cancer patients treated with 5-FU, epirubicin and cyclophosphamide.
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Constipation; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Flushing; Granisetron; Headache; Humans; Injections, Intravenous; Metoclopramide; Middle Aged; Nausea; Tablets; Vomiting | 1994 |
[Clinical evaluation of granisetron hydrochloride against nausea and vomiting induced by anticancer drugs for gynecological malignant tumors].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Granisetron; Humans; Middle Aged; Nausea; Ovarian Neoplasms; Uterine Neoplasms; Vomiting | 1996 |
Effects of granisetron with doxorubicin or epirubicin on ECG intervals.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antiemetics; Doxorubicin; Drug Interactions; Electrocardiography; Epirubicin; Female; Granisetron; Heart Rate; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasms; Serotonin Antagonists | 1996 |
Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Cost-Benefit Analysis; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Granisetron; Granulocyte Colony-Stimulating Factor; Humans; Indoles; Injections, Intravenous; Methotrexate; Middle Aged; Ondansetron; Serotonin Antagonists; Tropisetron; Vomiting | 1996 |
Delayed emesis induced by moderately emetogenic chemotherapy: do we need to treat all patients? The Italian Group for Antiemetic Research.
Topics: Acute Disease; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Dexamethasone; Double-Blind Method; Doxorubicin; Drug Therapy, Combination; Epirubicin; Female; Granisetron; Humans; Male; Middle Aged; Neoplasms; Prognosis; Time Factors; Vomiting | 1997 |
[Combination effect of granisetron plus corticosteroid for prevention of cisplatin-induced emesis: a cross-over study comparing methylprednisolone and dexamethasone].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cross-Over Studies; Dexamethasone; Drug Therapy, Combination; Endometrial Neoplasms; Epirubicin; Etoposide; Female; Granisetron; Humans; Methylprednisolone; Middle Aged; Nausea; Ovarian Neoplasms; Uterine Neoplasms; Vomiting | 1998 |
Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dopamine Antagonists; Double-Blind Method; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Glucocorticoids; Granisetron; Humans; Isonipecotic Acids; Methotrexate; Middle Aged; Nausea; Prednisolone; Serotonin Antagonists; Vomiting | 1999 |
Granisetron plus or minus alprazolam for emesis prevention in chemotherapy of lymphomas: a randomized multicenter trial. Granisetron Trialists Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alprazolam; Anti-Anxiety Agents; Antiemetics; Antineoplastic Agents; Cyclophosphamide; Dacarbazine; Doxorubicin; Epirubicin; Female; Granisetron; Humans; Lymphoma; Male; Middle Aged; Prednisone; Vomiting | 1999 |
Alprazolam significantly improves the efficacy of granisetron in the prophylaxis of emesis secondary to moderately emetogenic chemotherapy in patients with breast cancer.
Topics: Alprazolam; Anthracyclines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Over Studies; Cyclophosphamide; Doxorubicin; Drug Interactions; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Granisetron; Humans; Hypnotics and Sedatives; Middle Aged; Vomiting | 2005 |
[The feasibility of FEC (75) as adjuvant chemotherapy for Japanese breast cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Dexamethasone; Diarrhea; Drug Administration Schedule; Epirubicin; Feasibility Studies; Female; Fluorouracil; Granisetron; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neutropenia; Vomiting, Anticipatory | 2005 |
A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophospham
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dexamethasone; Double-Blind Method; Doxorubicin; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Granisetron; Humans; Middle Aged; Morpholines; Nausea; Palonosetron; Patient Reported Outcome Measures; Vomiting | 2020 |
6 other study(ies) available for granisetron and epirubicin
| Article | Year |
|---|---|
Interaction of the antiemetics ondansetron and granisetron with the cytotoxicity induced by irradiation, epirubicin, bleomycin, estramustine, and cisplatin in vitro.
Topics: Animals; Antibiotics, Antineoplastic; Antiemetics; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bleomycin; Cells, Cultured; Cisplatin; Cricetinae; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Interactions; Epirubicin; Estramustine; Fibroblasts; Granisetron; Humans; Lung Neoplasms; Ondansetron; Serotonin Antagonists; Tumor Cells, Cultured | 1995 |
[Successful antiemetic treatment of TSUMURA Rikkunshi-to Extract Granules for ethical use in addition to other antiemetic agents in neoadjuvant chemotherapy for an advanced breast cancer patient].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Dexamethasone; Drug Administration Schedule; Drugs, Chinese Herbal; Epirubicin; Female; Fluorouracil; Granisetron; Humans; Lymph Nodes; Lymphatic Metastasis; Mastectomy, Segmental; Metoclopramide; Middle Aged | 2006 |
Is there an association between PONV and chemotherapy-induced nausea and vomiting?
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Betamethasone; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease Resistance; Droperidol; Epirubicin; Female; Fluorouracil; Granisetron; Humans; Mastectomy; Methotrexate; Metoclopramide; Middle Aged; Models, Biological; Narcotics; Nausea; Ondansetron; Postoperative Nausea and Vomiting; Prospective Studies; Risk Factors; Vomiting | 2013 |
Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy: a multicenter, prospective, and observational study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Therapy, Combination; Epirubicin; Female; Granisetron; Humans; Middle Aged; Nausea; Palonosetron; Prospective Studies; Vomiting | 2019 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |